RE: Funds29 Jan 2025 09:35
Unwarranted drop after yesterday, company mcap should be significantly higher, compare to pharma peers. They have a drug which works across a range of unmet needs, where they already have the necessary data on efficacy and side effects, they could be treating patients as early as H1 of this year.